SCHEMBL9324845

SCHEMBL9324845

CN(C)CCC(C#N)c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 4/20 0.60
HRH1 P35367 4/20 0.60
SLC6A4 P31645 3/20 0.46
CHRM2 P08172 2/20 0.46
SLC6A2 P23975 2/20 0.46
SCN1A P35498 2/20 0.46
SCN2A Q99250 2/20 0.46
SCN3A Q9NY46 2/20 0.46
LMNA P02545 2/20 0.44
CYP2D6 P10635 2/20 0.44
OPRM1 P35372 2/20 0.44
DRD3 P35462 2/20 0.44
TSHR P16473 2/20 0.44
CYP1A2 P05177 1/20 0.44
CHRM4 P08173 1/20 0.44
CHRM5 P08912 1/20 0.44
ADRA2A P08913 1/20 0.44
CHRM1 P11229 1/20 0.44
ADRA2B P18089 1/20 0.44
CHRM3 P20309 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10573183 0.89 HTR2A (0.62) HTR2AHRH1SLC6A4CHRM2SLC6A2
SCHEMBL11647295 0.82 SIGMAR1 (0.54) HTR2AHRH1SLC6A4CHRM2SLC6A2
SCHEMBL6938022 0.82 HRH1 (0.44) HTR2AHRH1SLC6A4CHRM2LMNA
SCHEMBL23197244 0.82 HRH1 (0.39) HTR2AHRH1SLC6A4CHRM2SLC6A2
SCHEMBL11229227 0.82 CHRM2 (0.46) HTR2AHRH1SLC6A4CHRM2SLC6A2
SCHEMBL5879102 0.82 HRH1 (0.39) HTR2AHRH1SLC6A4CHRM2SLC6A2
SCHEMBL9192659 0.81 HTR2A (0.57) HTR2AHRH1SLC6A4CHRM2SLC6A2
SCHEMBL11237768 0.80 UTS2R (0.40) HTR2AHRH1
SCHEMBL953748 0.79 TRPA1 (0.43) HTR2AHRH1LMNATSHRCYP1A2
SCHEMBL9556340 0.77 ALDH1A1 (0.43) LMNATSHRHTTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12227501-B2 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as CSNK1 inhibitors BAYER AKTIENGESELLSCHAFT (DE) 2025-02-18 US disclosed
EP-3921317-B1 3-AMINO-2-[2-(ACYLAMINO)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE AS CSNK1 INHIBITORS BAYER AG (DE) 2023-08-02 EP disclosed
EP-3921317-B1 3-AMINO-2-[2-(ACYLAMINO)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE AS CSNK1 INHIBITORS BAYER AG (DE) 2023-08-02 EP disclosed
US-20230046077-A1 3-AMINO-2-[2-(ACYLAMINO)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE AS CSNK1 INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2023-02-16 US disclosed
US-20230046077-A1 3-AMINO-2-[2-(ACYLAMINO)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE AS CSNK1 INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2023-02-16 US disclosed
EP-3921317-A1 3-AMINO-2-[2-(ACYLAMINO)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE AS CSNK1 INHIBITORS Bayer Aktiengesellschaft (DE) 2021-12-15 EP disclosed
WO-2020161257-A1 3-AMINO-2-[2-(ACYLAMINO)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE AS CSNK1 INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2020-08-13 WO disclosed
WO-2020161257-A1 3-AMINO-2-[2-(ACYLAMINO)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE AS CSNK1 INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2020-08-13 WO disclosed
US-5308735-A Aromatic-aldehyde resins, improved solubility NIPPON PAINT CO., LTD. (JP) 1994-05-03 US disclosed
EP-0540016-A1 Photosensitive resin and resin composition for lithographic printing Nippon Paint Co., Ltd. (JP) 1993-05-05 EP disclosed
US-4847301-A Methods of use of α-(aminoalkyl)-arylacetic acid derivatives PENNWALT CORPORATION (US) 1989-07-11 US disclosed
US-4783537-A CARDIOVASCULAR DISORDERS PENNWALT CORPORATION (US) 1988-11-08 US disclosed
EP-0222099-A2 Alpha-(Aminoalkyl)-Arylacetic Acid Derivatives FISONS CORPORATION (a Massachusetts corporation) (US) 1987-05-20 EP disclosed
US-4324792-A SKIN DISORDERS, HAY FEVER, ASTHMA GLAXO GROUP LIMITED (GB) 1982-04-13 US disclosed
US-4049655-A 1,4-Dihydro-2H-isoquinoline derivatives HOECHST AKTIENGESELLSCHAFT (DT) 1977-09-20 US disclosed
US-3980655-A Basically substituted 1,4-dihydro-2H-isoquinoline derivatives and process for preparing them HOECHST AKTIENGESELLSCHAFT (DT) 1976-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230046077-A1 3-AMINO-2-[2-(ACYLAMINO)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE AS CSNK1 INHIBITORS CSNK1A1, CSNK1G1, CSNK1E HTR2A 4008/4885HRH1 2047/4885SLC6A4 4771/4885
US-12227501-B2 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as CSNK1 inhibitors CSNK1A1, CSNK1G1, CSNK1E HTR2A 4008/4885HRH1 2047/4885SLC6A4 4771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.